BioSpace News Archive

VESICA HEALTH, INC., a leading multi-omics liquid biopsy company dedicated to improving the management of hematuria patients and the early detection of bladder cancer, today announced the launch of its laboratory-developed AssureMDx™ test.

Mural Oncology plc announced that on May 1, the Company granted to three newly hired employees non-statutory stock options to purchase an aggregate of 20,150 ordinary shares of the Company and restricted stock units with respect to an aggregate of 10,850 ordinary shares of the Company, pursuant to the Company’s 2024 Inducement Stock Option and Incentive Plan.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 160,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 117,000 shares of Arcutis’ common stock to 13 newly hired employees.

Vor Bio announced that, effective as of May 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 31,750 shares of Vor Bio’s common stock and restricted stock units representing the right to receive an aggregate of 47,625 shares of Vor Bio’s common stock to six newly hired employees.

Anika Therapeutics, Inc. announced that on May 1, 2024, Anika granted non-statutory stock options covering an aggregate of 3,800 shares of common stock at a per share exercise price of $26.49, which equaled the closing price of common stock on the Nasdaq Global Select Market on the grant date, to one newly hired non-executive employee.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 4,150 restricted stock units of Atara’s common stock to one newly hired employee.

ORIC Pharmaceuticals, Inc. announced that on May 1, 2024, ORIC granted a total of 14,500 non-qualified stock options and 2,300 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2024.

Delcath Systems, Inc. announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of two individuals whose employment commenced in April 2024.

NovaBay® Pharmaceuticals, Inc. announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 8:00 a.m. ET.